Table 1.21 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2007^a Using Different Tumor Inclusion Criteriab

5-Year Limited Duration

32-year Limited Duration

<u>S</u> ite	Sex	lst Invasive Tumor Ever ^c	1st Per Site in Previous 32 Years ^d	1st Per Site in Previous 5 Years ^e	lst Invasive Tumor Ever ^c	1st Per Site in Previous 32 Years ^d
All Sites	Both Sexes Male	4,128,739 2,110,305	4,208,495 2,140,911	4,587,516 2,323,221	11,196,431 5,248,197	11,396,724 5,310,771
	Female	2,018,434	2,067,584	2,264,295	5,948,234	6,085,953
Oral Cavity &	Both Sexes	91,178	103,795	107,311	235,609	258,515
Pharynx	Male	62,485	70,353	72,387	153,118	166,208
	Female	28,693	33,442	34,924	82,491	92,307
Esophagus	Both Sexes	18,697	22,371	22,384	28,549	33,324
	Male	14,341	17,140	17,153	21,695	25,162
	Female	4,356	5,231	5,231	6,854	8,162
Stomach	Both Sexes	32,686	39,128	39,293	63,730	72,980
	Male	19,323	23,318	23,348	36,215	41,618
	Female	13,363	15,810	15,945	27,515	31,362
Colon & Rectum	Both Sexes	404,997	468,117	476,559	1,076,622	1,199,140
	Male	202,765	234,821	238,838	527,903	584,590
	Female	202,232	233,296	237,721	548,719	614,550
Liver &	Both Sexes	20,688	23,505	23,517	27,353	30,585
Intrahepatic	Male	14,728	16,576	16,588	18,577	20,660
Bile Duct	Female	5,960	6,929	6,929	8,776	9,925
Pancreas	Both Sexes	24,579	29,347	29,358	32,616	38,193
	Male	12,128	14,558	14,569	15,897	18,650
	Female	12,451	14,789	14,789	16,719	19,543
Larynx	Both Sexes	30,163	35,886	36,142	87,367	97,387
	Male	23,925	28,340	28,574	69,746	77,350
	Female	6,238	7,546	7,568	17,621	20,037
Lung & Bronchus	Both Sexes	213,542	267,851	273,542	360,606	436,310
	Male	100,425	126,335	128,613	167,066	201,817
	Female	113,117	141,516	144,929	193,540	234,493
Melanoma of	Both Sexes	242,029	271,164	281,289	751,279	806,659
the Skin	Male	127,243	145,557	152,065	371,049	402,671
	Female	114,786	125,607	129,224	380,230	403,988
Breast	Female	796,935	857,596	904,022	2,509,315	2,661,082
Cervix	Female	38,618	40,422	40,532	195,066	200,672
Corpus & Uterus, NOS	Female	148,471	167,653	167,699	527,264	573,628
Ovary ^f	Female	53,433	62,494	62,552	156,901	176,514

U.S. 2007 cancer prevalence counts are based on 2007 cancer prevalence proportions from the SEER 9 registries and 1/1/2007 U.S. population estimates based on the average of 2006 and 2007 population estimates from the U.S. Bureau of the Census.

d

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

⁽c) First invasive tumor ever
(d) First invasive tumor for each cancer site diagnosed during the previous 32 years (1975-2006)
(e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2002-2006)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2002;

Melanoma in 2003.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 32-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2007. In method (d) the 1981 melanoma is counted for the melanoma and all sites 32-year limited duration prevalence. The 2002 breast cancer is counted for the breast 5-year and 32-year limited duration prevalence.

In method (e) the 2002 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2003 melanoma is counted for 5-year limited duration prevalence for melanoma.

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2007^a Using Different Tumor Inclusion Criteriab

5-Year Limited Duration

32-year Limited Duration

Site	Sex	1st Invasive Tumor Ever ^c	1st Per Site in Previous 32 Years ^d	lst Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 32 Years ^d
Prostate	Male	938,613	1,013,875	1,013,911	2,273,570	2,425,802
Testis	Male	39,905	40,672	41,227	179,020	181,360
Urinary Bladder	Both Sexes	189,135	233,199	237,692	518,286	598,692
	Male	141,812	175,570	179,094	384,498	443,555
	Female	47,323	57,629	58,598	133,788	155,137
Kidney &	Both Sexes	118,493	143,522	144,764	270,625	314,100
Renal Pelvis	Male	70,932	86,672	87,600	158,850	185,673
	Female	47,561	56,850	57,164	111,775	128,427
Brain &	Both Sexes	40,293	42,551	42,885	112,726	116,105
Nervous System	Male	22,134	23,505	23,659	60,362	62,268
Norvous System	Female	18,159	19,046	19,226	52,364	53,837
Thyroid	Both Sexes	129,436	141,554	141,860	392,263	415,126
	Male	28,915	33,014	33,071	86,537	93,189
	Female	100,521	108,540	108,789	305,726	321,937
Hodgkin Lymphoma	Both Sexes	36,160	38,130	38,141	149,892	153,535
	Male	18,823	19,773	19,784	77,318	79,103
	Female	17,337	18,357	18,357	72,574	74,432
Non-Hodgkin Lymphoma	Both Sexes Male Female	182,913 95,299 87,614	212,380 111,717 100,663	213,902 112,437 101,465	427,401 221,132 206,269	474,880 245,677 229,203
Maralana	Both Sexes	40,775	47,047	47,082	61,360	69,598
Myeloma	Male	21,757	25,411	25,446	33,418	38,267
	Female	19,018	21,636	21,636	27,942	31,331
Leukemia	Both Sexes	99,568	112,939	113,079	238,435	259,889
	Male	57,160	65,055	65,125	134,732	147,037
	Female	42,408	47,884	47,954	103,703	112,852
Acute	Both Sexes	15,056	15,397	15,397	57,526	58,016
Lymphocytic	Male	8,617	8,718	8,718	31,667	31,805
Leukemia	Female	6,439	6,679	6,679	25,859	26,211
Childhood	Both Sexes	59,446	59,545	59,919	269,403	269,864
(Ages 0-19)	Male	32,002	32,057	32,201	138,408	138,607
	Female	27,444	27,488	27,718	130,995	131,257
Kaposi Sarcoma	Both Sexes	6,329	6,781	6,781	21,513	22,595
	Male	5,909	6,235	6,235	20,237	21,145
	Female	420	546	546	1,276	1,450
Mesothelioma	Both Sexes	2,943	3,641	3,641	4,427	5,271
	Male	2,066	2,537	2,537	2,655	3,237
	Female	877	1,104	1,104	1,772	2,034

U.S. 2007 cancer prevalence counts are based on 2007 cancer prevalence proportions from the SEER 9 registries and 1/1/2007 U.S. population estimates based on the average of 2006 and 2007 population estimates from the U.S. Bureau of the Census.

d

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2002;

Melanoma in 2003.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 32-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2007. In method (d) the 1981 melanoma is counted for the melanoma and all sites 32-year limited duration prevalence. The 2002 breast cancer is counted for the breast 5-year and 32-year

limited duration prevalence.

In method (e) the 2002 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2003 melanoma is counted for 5-year limited duration prevalence for melanoma.

Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

(c) First invasive tumor ever

(d) First invasive tumor for each cancer site diagnosed during the previous 32 years (1975-2006)

(e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2002-2006)

For definitions (d) and (e) all sites is treated as a separate garger "site"

For definitions (d) and (e) all sites is treated as a separate cancer "site"

Table 1.22 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2007a By Age at Prevalence

	Age at Prevalence								
Site/Sex	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	5,353,054	17,384	39,980	78,051	145,588	336,123	749,038	1,258,920	2,727,970
Females	6,360,682	15,217	33,503	84,509	213,851	604,412	1,155,959	1,395,096	2,858,136
Oral Cavity & Pharynx									
Males	161,112	34	462	1,460	3,306	14,446	38,574	42,305	60,526
Females	88,254	112	478	1,499	3,730	8,328	16,027	18,737	39,343
Esophagus									
Males	21,782	0	0	16	110	1,155	4,158	7,094	9,250
Females	6,947	0	0	12	71	215	906	1,589	4,154
Stomach									
Males	37,297	0	5	29	621	2,421	5,852	9,147	19,223
Females	28,342	5	11	106	575	2,139	3,970	4,882	16,654
Colon & Rectum									
Males	540,636	11	46	1,079	5,377	23,458	70,527	118,887	321,251
Females	571,857	0	109	1,421	4,924	21,129	59,895	98,155	386,224
Liver & Intrahep									
Males	18,644	408	525	363	435	1,451	6,731	4,464	4,268
Females	9,109	411	346	356	427	842	1,852	1,835	3,041
Pancreas									
Males	16,057	0	23	93	227	1,283	3,502	4,577	6,353
Females	16,936	0	53	137	418	1,208	3,029	4,061	8,031
Larynx									
Males	72,246	0	0	24	215	2,470	10,579	19,435	39,524
Females	18,192	0	0	57	77	1,144	3,131	4,429	9,355
Lung & Bronchus									
Males	172,739	34	75	375	1,109	6,021	23,958	50,028	91,141
Females	197,878	11	55	332	1,269	8,266	26,154	53,184	108,608
Melanoma of the Skin									
Males	385,054	94	750	5,271	16,607	46,961	86,015	93,408	135,947
Females	408,229	72	991	11,270	32,943	70,027	96,409	80,585	115,933

U.S. 2007 cancer prevalence counts are based on 2007 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2007 U.S. population estimates based on the average of 2006 and 2007 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Cases diagnosed more than 32 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2007ª By Age at Prevalence

	Age at Prevalence								
Site/Sex	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Post and									
Breast	40.006	•				400			= 0.40
Males	13,326	0	0	29	93	497	2,014	3,353	7,340
Females	2,591,855	0	81	2,530	35,087	208,053	505,550	645,055	1,195,498
Cervix									
Females	247,180	11	81	2,348	17,537	43,343	58,279	48,897	76,684
Corpus & Uterus, NOS									
Females	575,108	0	67	452	5,116	23,123	78,436	129,723	338,192
Ovary ^d									
_	100 160	0.4	0.40	2 551	6 506	00 110	25 516	40.600	65 220
Females	177,162	84	949	3,571	6,786	20,117	37,716	40,600	67,339
Prostate									
Males	2,276,112	50	69	80	387	17,453	197,739	585,651	1,474,683
Urinary Bladder									
Males	395,480	11	131	702	2,434	12,104	42,058	87,203	250,837
Females	139,756	33	46	342	1,153	4,415	13,116	27,208	93,443
Kidney & Renal Pelvis									
Males	164,839	1,413	2,428	2,472	4,088	14,777	33,714	43,718	62,228
Females	116,651	1,441	2,633	2,809	3,988	10,792	19,272	25,537	50,178
Hodgkin Lymphoma									
Males	84,583	162	2,193	9,019	16,237	22,676	18,661	9,862	5,771
	•			•					•
Females	79,690	107	1,397	10,426	16,314	21,812	16,409	7,293	5,934
Non-Hodgkin Lymphoma									
Males	226,855	689	3,434	7,073	12,028	27,188	44,816	51,557	80,070
Females	211,470	393	1,596	4,130	7,622	18,650	37,239	45,364	96,476
Myeloma									
Males	33,522	0	5	40	488	2,380	6,786	9,878	13,944
Females	28,120	0	0	23	215	1,671	5,234	7,536	13,441
Leukemia									
Males	137,398	6,452	11,601	11,047	9,522	11,671	18,275	24,790	44,041
Females	106,874	5,226	9,722	9,893	8,060	8,514	12,311	15,613	37,535
Acute Lymphocytic Leuk									
Males	33,394	5,340	10,132	8,470	5,396	2,320	905	538	291
Maies Females	27,389	4,366	8,155	7,282	4,309	2,320 1,895	706	455	220
rellates	21,309	4,300	0,133	1,202	4,309	1,095	700	455	220

U.S. 2007 cancer prevalence counts are based on 2007 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2007 U.S. population estimates based on the average of 2006 and 2007 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Cases diagnosed more than 32 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.